Andrew M Scott

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. pmc Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
    C Panousis
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Level 1, Harold Stokes Building, Austin Hospital, 145 163 Studley Road, Heidelberg 3084, Victoria, Australia
    Br J Cancer 92:1069-77. 2005
  2. pmc Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
    Andrew M Scott
    Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology Unit, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
    EJNMMI Res 2:31. 2012
  3. doi request reprint Antibody therapy of cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research University of Melbourne and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia
    Nat Rev Cancer 12:278-87. 2012
  4. doi request reprint Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia
    Eur J Nucl Med Mol Imaging 36:347-53. 2009
  5. doi request reprint PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study
    Andrew M Scott
    Department of Medicine, University of Melbourne, Melbourne, Australia
    J Nucl Med 49:1593-600. 2008
  6. ncbi request reprint A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Australia
    Clin Cancer Res 13:3286-92. 2007
  7. ncbi request reprint PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Melbourne, Australia
    J Nucl Med 49:1451-7. 2008
  8. pmc A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
    Andrew M Scott
    Ludwig Institute for Cancer Research, 143 165 Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 104:4071-6. 2007
  9. ncbi request reprint A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Melbourne, Victoria, Australia
    Clin Cancer Res 11:4810-7. 2005
  10. pmc Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
    Prostate 69:92-104. 2009

Detail Information

Publications91

  1. pmc Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
    C Panousis
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Level 1, Harold Stokes Building, Austin Hospital, 145 163 Studley Road, Heidelberg 3084, Victoria, Australia
    Br J Cancer 92:1069-77. 2005
    ..These results support a potential therapeutic role of ch806 in the treatment of suitable EGFR-expressing tumours, and warrants further investigation of the potential of ch806 as a therapeutic agent...
  2. pmc Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
    Andrew M Scott
    Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology Unit, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
    EJNMMI Res 2:31. 2012
    ..abstract:..
  3. doi request reprint Antibody therapy of cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research University of Melbourne and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia
    Nat Rev Cancer 12:278-87. 2012
    ..This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials...
  4. doi request reprint Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia
    Eur J Nucl Med Mol Imaging 36:347-53. 2009
    ..Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans...
  5. doi request reprint PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study
    Andrew M Scott
    Department of Medicine, University of Melbourne, Melbourne, Australia
    J Nucl Med 49:1593-600. 2008
    ..Secondary aims were to determine the incremental staging information provided by PET and to document the effect of PET on treatment outcomes...
  6. ncbi request reprint A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Australia
    Clin Cancer Res 13:3286-92. 2007
    ..We report a first-in-man trial of a humanized antibody (hu3S193) against the Le(y) antigen...
  7. ncbi request reprint PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Melbourne, Australia
    J Nucl Med 49:1451-7. 2008
    ..The aims of our study were to examine the impact of PET in changing management in patients with proven or suspected colorectal cancer recurrence and to assess the impact of management change on disease-free survival...
  8. pmc A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
    Andrew M Scott
    Ludwig Institute for Cancer Research, 143 165 Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 104:4071-6. 2007
    ..These in vitro and in vivo characteristics of ch806 distinguish it from all other antibodies targeting EGFR...
  9. ncbi request reprint A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Melbourne, Victoria, Australia
    Clin Cancer Res 11:4810-7. 2005
    ..To determine the in vivo characteristics of huA33, a CDR-grafted humanized antibody against the A33 antigen, we have conducted an open-label, dose escalation, biopsy-based phase I trial of huA33 in patients with colorectal carcinoma...
  10. pmc Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
    Prostate 69:92-104. 2009
    ..The ability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 and docetaxel chemotherapy to enhance the efficacy of RIT was also assessed in vivo...
  11. ncbi request reprint Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478
    Fook T Lee
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:7080s-7086s. 2005
    ..This study investigated the effect of EGFR tyrosine kinase inhibition on the efficacy of radioimmunotherapy in a human cancer xenograft model...
  12. pmc Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Cancer Biother Radiopharm 23:411-23. 2008
    ..However, limited in vitro stability and high renal localization of radiolabeled constructs were observed, which, despite the observed tumor targeting of the hu3S193 multimer, most likely preclude its use in RIT and imaging modalities...
  13. ncbi request reprint Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 13:5604s-5612s. 2007
    ..Therefore, we have investigated the efficacy of the alpha-particle-emitting bismuth-213 (213Bi) radioimmunotherapy using the humanized anti-Lewis Y (Ley) monoclonal antibody humanized 3S193 (hu3S193)...
  14. ncbi request reprint Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor
    Terrance G Johns
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg 3084, Australia
    J Biol Chem 279:30375-84. 2004
    ..Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity...
  15. ncbi request reprint Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    J Nucl Med 47:716-25. 2006
    ..The rationale for this combined-modality RIT (CMRIT) was to increase the therapeutic efficacy of RIT through the use of paclitaxel to arrest cells in the radiosensitive G(2)/M phase of the cell cycle...
  16. ncbi request reprint The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806
    Hui K Gan
    Oncogenic Signalling Laboratory, Ludwig Institute of Cancer Research, Austin Hospital, Level 6, Harold Stokes Building, Studley Road, Heidelberg, Victoria 3084, Australia
    J Biol Chem 282:2840-50. 2007
    ..This information was used to optimize the therapeutic synergy between mAb 806 and AG1478 in a xenograft model...
  17. ncbi request reprint Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806
    Fook T Lee
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    J Nucl Med 51:967-72. 2010
    ..The aim of this study was to develop a PET-based method for detecting the constitutively active mutant de2-7 EGFR, which is associated with disease progression and resistance to chemotherapy and radiotherapy in glioma...
  18. ncbi request reprint Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET
    Martin H Cherk
    Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
    J Nucl Med 47:1921-6. 2006
    ....
  19. ncbi request reprint Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies
    Lawrence M Cher
    Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
    J Nucl Med 47:410-8. 2006
    ....
  20. pmc Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
    Jennifer A Westwood
    Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 102:19051-6. 2005
    ..This study supports the use of humanized gene-modified T cells as a potential therapy for Le(Y+) malignancies...
  21. pmc Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody
    Rushika M Perera
    Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    Neoplasia 9:1099-110. 2007
    ..These results highlight the potential use of mAb 806 for generation of conjugates suitable for diagnostic and therapeutic use in patients with EGFR-positive malignancies...
  22. doi request reprint Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans
    Joe H Chang
    Radiation Oncology Centre, Austin Health, Victoria, Australia
    Int J Radiat Oncol Biol Phys 83:e691-6. 2012
    ..To demonstrate the technical feasibility of intensity modulated radiation therapy (IMRT) dose painting using (11)C-choline positron emission tomography PET scans in patients with localized prostate cancer...
  23. pmc A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:14. 2007
    ..No antitumour responses were observed. In conclusion, weekly cG250 with daily low-dose subcutaneous IL-2 is well tolerated. IL-2 does not influence cG250 biodistribution or increase HACA...
  24. ncbi request reprint Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study
    Joe H Chang
    Radiation Oncology Centre, Austin Health, Victoria, Australia
    Acta Oncol 52:1723-9. 2013
    ..This study investigates the use of (18)F-fluoromisonidazole (FMISO) PET-guided radiotherapy dose painting for potentially overcoming the radioresistant effects of hypoxia in head and neck squamous cell carcinoma (HNSCC)...
  25. ncbi request reprint Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity
    Rushika M Perera
    Ludwig Institute for Cancer Research, Melbourne Branch, Tumor Targeting Program, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:6390-9. 2005
    ..Thus, mAb 806 can synergize with other EGFR-specific antibodies thereby providing a rationale for its translation into the clinic...
  26. ncbi request reprint The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization
    Terrance G Johns
    Oncogenic Signalling Laboratory and Tumor Targeting Program, Ludwig Institute for Cancer Research, Melbourne Centre, Austin Hospital, Heidelberg, Melbourne, Australia
    Clin Cancer Res 13:1911-25. 2007
    ..Factors affecting the efficacy of therapeutic monoclonal antibodies (mAb) directed to the epidermal growth factor receptor (EGFR) remain relatively unknown, especially in glioma...
  27. ncbi request reprint Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Victoria, 3084, Australia
    Cancer Immun 5:3. 2005
    ..The favourable immune properties of KM871, combined with this preliminary clinical data, indicate that KM871 has potential for the treatment of metastatic melanoma...
  28. ncbi request reprint MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor
    Terrance G Johns
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Int J Radiat Oncol Biol Phys 78:572-8. 2010
    ..We have previously shown that mAb 806, a novel EGFR-specific antibody, is able to inhibit the growth of U87MG.Δ2-7 glioma xenografts expressing the de2-7 EGFR and may have potential as a therapeutic...
  29. doi request reprint Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT
    Nathan Lawrentschuk
    University of Melbourne Department of Surgery, Austin Hospital, Melbourne, Victoria, Australia
    Urol Oncol 29:411-20. 2011
    ....
  30. ncbi request reprint Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine
    Rebecca A Herbertson
    Ludwig Institute for Cancer Research, Melbourne, Australia
    J Nucl Med 55:534-9. 2014
    ..The primary objective was safety and tolerability of the combination of capecitabine and (131)I-huA33. Pharmacokinetics, biodistribution, immunogenicity, and tumor response were also assessed...
  31. ncbi request reprint Xenografting tumour beneath the renal capsule using modern surgical equipment
    Nathan Lawrentschuk
    Department of Surgery and Urology, Tumour Targetting Laboratory, Austin Hospital, Heidelberg, Vic, Australia
    Eur Surg Res 38:340-6. 2006
    ..We report on a novel method for human renal tumour transplants using an automated biopsy gun to obtain tumour tissue and an epidural needle with introducer to easily deploy the grafts under the renal capsule...
  32. ncbi request reprint The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor
    Terrance G Johns
    Ludwig Institute for Cancer Research, Tumour Targeting Program, Austin Hospital, Heidelberg, Australia
    FASEB J 19:780-2. 2005
    ..As our observations are likely to apply to other receptors overexpressed in cancer, they suggest a strategy for developing antitumor antibodies even when the target receptor is expressed in normal tissue...
  33. ncbi request reprint Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma
    Geoffrey Chong
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 11:4818-26. 2005
    ..Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose...
  34. pmc Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
    Terrance G Johns
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg 3084, Australia
    Proc Natl Acad Sci U S A 100:15871-6. 2003
    ..These results establish the antitumor efficacy of the EGFR inhibitor AG1478 and provide a rationale for its clinical evaluation in combination with both chemotherapy and other EGFR therapeutics...
  35. ncbi request reprint Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871
    Zhanqi Liu
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Heidelberg, Victoria, 3084, Australia
    Cancer Immun 2:13. 2002
    ..Furthermore, ADCC was significantly reduced using NK-depleted PBMCs. These results suggest combining IL-2 or IL-12 with KM871 may enhance KM871 immune-mediated cell killing in patients with metastatic melanoma...
  36. ncbi request reprint Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Victoria, Australia
    BJU Int 96:540-6. 2005
    ....
  37. ncbi request reprint Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Australia
    BJU Int 97:916-22. 2006
  38. ncbi request reprint Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole
    Sze Ting Lee
    Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Semin Nucl Med 37:451-61. 2007
    ..This review discusses the relevance and biology of hypoxia in cells and organ systems, and reviews the laboratory and clinical applications of (18)F-FMISO in oncology and noncancer disease states...
  39. ncbi request reprint Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
    Rebecca A Herbertson
    Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
    Clin Cancer Res 15:6709-15. 2009
    ..This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Le(y) antigen...
  40. ncbi request reprint The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
    Rodney B Luwor
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin Hospital, Heidelberg 3084, Australia
    Oncogene 23:6095-104. 2004
    ..This observation is directly relevant to glioma where de2-7 and wt EGFR appear to be coexpressed. Thus, expression of de2-7 EGFR in BaF/3 cells provides an in vitro model for evaluating the signalling pathways activated by this receptor...
  41. doi request reprint Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    Andrew J Weickhardt
    Ludwig Institute for Cancer Research, Australia
    J Clin Oncol 30:1505-12. 2012
    ..This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC)...
  42. pmc The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases
    Vinochani Pillay
    Ludwig Institute for Cancer Research, Heidelberg, Victoria 3084, Australia
    Neoplasia 11:448-58, 2 p following 458. 2009
    ..Consequently, inhibition of a dominant oncogene by targeted therapy can alter the hierarchy of RTKs resulting in rapid therapeutic resistance...
  43. ncbi request reprint Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents
    Christopher Vearing
    Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
    Cancer Res 65:6745-54. 2005
    ..These findings show the biological importance of EphA3/ephrin-A5 interactions and that ephrin-A5 and IIIA4 have great potential as tumor targeting reagents...
  44. ncbi request reprint Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model
    Kiki Tahtis
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin, Victoria 3084, Australia
    Mol Cancer Ther 2:729-37. 2003
    ....
  45. pmc A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:13. 2007
    ..In conclusion, repeated intravenous doses of up to 50 mg/m(2) of cG250 are safe. Furthermore cG250 has a long half-life and targets clear cell RCC effectively...
  46. pmc Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET
    Sameer A Greenall
    Oncogenic Signaling Laboratory, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia
    PLoS ONE 7:e34658. 2012
    ....
  47. ncbi request reprint Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses
    Zhanqi Liu
    Tumor Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Tumor Biology Branch, Austin and Repatriation Medical Centre, 145 164 Studley Road, Heidelberg, Victoria 3084, Australia
    Hybrid Hybridomics 22:219-28. 2003
    ....
  48. pmc Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism
    Anna N Cvrljevic
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Heidelberg, Victoria 3084, Australia
    J Cell Sci 124:2938-50. 2011
    ..Thus, the mitochondrial localisation of de2-7EGFR contributes to its tumorigenicity and might help to explain its resistance to some EGFR-targeted therapeutics...
  49. doi request reprint Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy
    Joe H Chang
    Radiation Oncology Centre, Austin Health, Victoria, Australia
    Radiother Oncol 99:187-92. 2011
    ..To evaluate the accuracy of (11)C-choline PET scans in defining dominant intraprostatic lesions (DILs) for radiotherapy target volume definition...
  50. doi request reprint Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization
    Hui K Gan
    Oncogenic Signalling Laboratory, Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Australia
    J Cell Mol Med 13:3993-4001. 2009
    ..Given the increase in VEGF, we combined mAb 806 with bevacizumab in vivo, resulting in additive activity...
  51. ncbi request reprint Positron emission tomography and molecular imaging of the prostate: an update
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Australia
    BJU Int 97:923-31. 2006
  52. pmc Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer
    Anthony Hannah
    Centre for Positron Emission Tomography, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Ann Surg 236:208-17. 2002
    ..To prospectively evaluate the use of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in the initial staging of squamous cell head and neck carcinoma...
  53. doi request reprint Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers
    Noga Kozer
    Ludwig Institute for Cancer Research, Melbourne Parkville Branch, Royal Melbourne Hospital, Victoria 3050, Australia
    Biochemistry 50:3581-90. 2011
    ..The results reveal new modes of receptor-antibody interactions for EGFR and de2-7-EGFR...
  54. ncbi request reprint Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957
    Uwe Ackermann
    Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia
    Nucl Med Biol 32:323-8. 2005
    ..3+/-2.1% (n=3; not decay corrected) and an average specific radioactivity of 40 GBq/micromol (1.1 Ci/micromol) at the end of synthesis. The total synthesis time from EOB including HPLC purification and formulation was 45 min...
  55. ncbi request reprint Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene
    Terrance G Johns
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne, Australia
    Int J Cancer 98:398-408. 2002
    ..Thus, MAb 806 can be used to target tumor cells containing amplification of the EGFR gene or de2-7 EGFR but does not bind to the wild type EGFR when expressed on the cell surface...
  56. ncbi request reprint Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer
    Kelvin K Yap
    Centre for PET, University of Melbourne, Austin Hospital Heidelberg, Victoria, 3084, Australia
    Eur J Nucl Med Mol Imaging 32:1033-40. 2005
    ....
  57. ncbi request reprint Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma
    Marion T Harris
    Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
    Mol Imaging Biol 7:304-8. 2005
    ....
  58. ncbi request reprint Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity
    Zhanqi Liu
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    Cancer Immunol Immunother 51:171-7. 2002
    ....
  59. ncbi request reprint Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies
    Paul Mitchell
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Melbourne, Victoria, Australia
    J Nucl Med 44:1105-12. 2003
    ..CD19 is highly expressed (CD19(+)) on ALL cells and is an attractive target for antibody-based therapies. CLB-CD19 is an IgG1kappa murine monoclonal antibody (mAb) directed against an epitope on the CD19 antigen...
  60. ncbi request reprint High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer
    Arun Azad
    Ludwig Institute Oncology Unit, Austin Health, Heidelberg, Australia
    Mol Imaging Biol 12:443-51. 2010
    ..We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC)...
  61. ncbi request reprint Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice
    Nathan Lawrentschuk
    University of Melbourne, Department of Surgery, Victoria, Australia
    Int J Urol 14:89-95. 2007
    ..This article summarizes the current diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer with particular reference to radionuclide bone scintigraphy and positron emission tomography...
  62. ncbi request reprint Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy
    Glenn P Ollenberger
    Department of Nuclear Medicine and Centre for PET, University of Melbourne, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 32:1311-6. 2005
    ..We performed a retrospective analysis of the results of FDG PET scans in children with refractory epilepsy referred to our centre over an 8-year period, with a view to ascertaining the impact of FDG PET on subsequent patient management...
  63. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  64. doi request reprint Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer
    David S Binns
    The Peter MacCallum Cancer Centre, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 38:642-50. 2011
    ..Molecular imaging assessments, including changes in (18)F-deoxyglucose (FDG) or (18)F-deoxythymidine (FLT) uptake by positron emission tomography (PET), may provide earlier, more robust evaluation of treatment efficacy...
  65. doi request reprint Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder
    James S Olver
    Department of Psychiatry, University of Melbourne, Heidelberg, Victoria, Australia
    Psychiatry Res 183:85-8. 2010
    ..These findings suggest mesocortical dopamine inputs via D(1) receptors may play a role in the aetiology of OCD...
  66. doi request reprint Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy
    Hui K Gan
    Joint Austin Ludwig Medical Oncology Unit, Austin Hospital, Australia
    Cancer Res 72:2924-30. 2012
    ..This concept of conformational epitope targeting by antibodies reflects an underlying interplay between the structure and biology of different conformational forms of the EGFR family...
  67. ncbi request reprint Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer
    Elizabeth Yuriev
    Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University, Victoria, Australia
    Immunol Cell Biol 83:709-17. 2005
    ....
  68. doi request reprint The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum
    Jennifer A Westwood
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
    J Immunother 32:292-301. 2009
    ....
  69. pmc A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody
    William Farrugia
    Centre for Immunology, Burnet Institute, Melbourne, Victoria, Australia
    PLoS ONE 4:e7777. 2009
    ..A humanized Le(y)-specific antibody (hu3S193) has shown encouraging safety, pharmacokinetic and tumor-targeting properties in recently completed Phase I clinical trials...
  70. ncbi request reprint Immuno-PET for tumor targeting
    Fook T Lee
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Centre for PET, Austin Hospital, 145 163 Studley Road, Heidelberg, Victoria 3084, Australia
    J Nucl Med 44:1282-3. 2003
  71. ncbi request reprint Therapeutic targeting of the epidermal growth factor receptor in human cancer
    Nathalie S Dhomen
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Crit Rev Oncog 17:31-50. 2012
    ....
  72. ncbi request reprint Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens
    Paul A Ramsland
    Structural Immunology Laboratory, Austin Research Institute, Heidelberg, VIC 3084, Australia
    J Mol Biol 340:809-18. 2004
    ..Closely related blood-group determinants (Le(a) and Le(b)) cannot enter the specificity pocket, making the Le(y) antibodies promising candidates for immunotherapy of epithelial cancer...
  73. ncbi request reprint CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor
    Francesca Walker
    Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    J Biol Chem 279:22387-98. 2004
    ....
  74. ncbi request reprint Functional imaging of intratumoral hypoxia
    Serene S Foo
    Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Victoria, Australia
    Mol Imaging Biol 6:291-305. 2004
    ..Recent evidence that hypoxia also influences the regulation and transcription of various genes involved in malignant growth and metastases, and promotes a more aggressive tumor phenotype makes its diagnosis even more important...
  75. ncbi request reprint Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    J Clin Oncol 24:4228-35. 2006
    ....
  76. ncbi request reprint Radiation dose to PET technologists and strategies to lower occupational exposure
    Fiona O Roberts
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
    J Nucl Med Technol 33:44-7. 2005
    ..The use of PET in Australia has grown rapidly. We conducted a prospective study of the radiation exposure of technologists working in PET and evaluated the occupational radiation dose after implementation of strategies to lower exposure...
  77. ncbi request reprint Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO)
    Henri J Tochon-Danguy
    Centre for PET, Austin and Repatriation Medical Centre, 3084, Melbourne, Victoria, Australia
    Nucl Med Biol 29:191-7. 2002
    ..Quantitation of uptake of FMISO showed a tumor/brain ratio of 1.9 and a tumor/blood ratio of 2.6 at 2 hours post injection...
  78. ncbi request reprint Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography
    Serene S Foo
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Victoria, Australia
    Australas Radiol 48:214-6. 2004
    ..Assessment of glucose metabolism with FDG PET might represent a more powerful tool to detect bone metastases in lung cancer compared with conventional bone scans...
  79. ncbi request reprint Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel
    Shinichi Kageyama
    Department of Immuno Gene Therapy, Mie University Graduate School of Medicine, 2 174 Edobashi, Tsu, Mie 514 8507, Japan
    Cancer Sci 99:601-7. 2008
    ..Our results indicate that CHP-HER2 induced HER2-specific humoral responses in patients with HER2-expressing tumors and that GM-CSF seems to accelerate the responses...
  80. ncbi request reprint A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
    Clin Cancer Res 9:1639-47. 2003
    ....
  81. ncbi request reprint Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein
    Stefan Bauer
    Medical Department I, Universitat des Saarlandes, Homburg Saar, Germany
    J Immunol 172:3930-9. 2004
    ..These data warrant transfer of the anti-FAP-TNF immunocytokine into clinical trials for the treatment of FAP-positive tumors...
  82. ncbi request reprint Radioimmunotherapy of prostate cancer: does tumor size matter?
    Andrew M Scott
    J Clin Oncol 23:4567-9. 2005
  83. ncbi request reprint Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'
    David J Macfarlane
    Department of Nuclear Medicine, Royal Brisbane and Women s Hospital, Australia
    Eur J Nucl Med Mol Imaging 33:648-56. 2006
    ..The purpose of this study was to evaluate the safety, pharmacokinetics and dosimetry of four increasing doses of (99m)Tc-DI-80B3 Fab' in healthy volunteers...
  84. ncbi request reprint Novel imaging techniques in melanoma
    Richard Essner
    Department of Surgical Oncology and Molecular Therapeutics, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Surg Oncol Clin N Am 15:253-83. 2006
    ..In translational research, [18F]fluorodeoxyglucose probes have been designed to optimize the detection of melanoma tumor sites in vivo...
  85. ncbi request reprint Role of nuclear medicine in the management of cutaneous malignant melanoma
    Tarik Z Belhocine
    Department of Diagnostic Radiology and Nuclear Medicine, St Joseph s Hospital, London, Ontario, Canada
    J Nucl Med 47:957-67. 2006
    ..In this article, we review the role of nuclear medicine in the assessment of malignant melanoma...
  86. ncbi request reprint A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma
    Junichi Sakamoto
    Department of Epidemiological and Clinical Research Information Management, Kyoto University, Kyoto 606 8501, Japan
    Cancer Sci 97:1248-54. 2006
    ....
  87. ncbi request reprint HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan
    Shigehisa Kitano
    Department of Medical Oncology and Immunology, Mie University Graduate School of Medicine, Japan
    Clin Cancer Res 12:7397-405. 2006
    ....
  88. ncbi request reprint Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne 8006, Australia
    Eur J Nucl Med Mol Imaging 32:1384-91. 2005
    ..The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy...
  89. ncbi request reprint Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
    J Thorac Oncol 2:947-52. 2007
    ..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies...
  90. pmc A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:639-44. 2003
    ..Our study also indicates that DeltaEGFR is restricted to glioblastoma, in contrast to other reports that this mutation is found in tumors outside the brain...
  91. pmc Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody
    Barbara E Power
    CSIRO Health Sciences and Nutrition, Parkville, Victoria 3052, Australia
    Protein Sci 12:734-47. 2003
    ....